Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

MRI findings in Neurosarcoidosis Patients with Headache as a Primary Presenting Symptom
Headache
Headache Posters (7:00 AM-5:00 PM)
079
Neurologic complications occur in approximately 5 to 10 percent of patients with sarcoidosis. Clinical manifestations include cranial nerve palsies, sensory and/or motor deficits, and, commonly, persistent headache. The typical work-up of these patients includes a contrast enhanced brain MRI.
To determine if there are MRI differences in patients with neurosarcoidosis, who present with headache as a primarily clinical symptom, compared with those who initially present with non-headache symptomatology. To the author’s knowledge, this has not been previously reported in the available literature.
This is an IRB-approved retrospective chart review  conducted at an urban tertiary care center. 123 patients with Neurosarcoidosis were identified between the years 1980 and 2018 , of whom 110 had a completed MRI at the time of diagnosis. These patients were then separated into two groups. Group A included patients who reported headache as their primary neurological complaint, while group B included patients whose presenting neurological symptom was other than headache. Available brain MRI reports were reviewed for each of these patients. Chi-square test was used for analysis.
Out of the 110 patients, headache was an initial presenting symptom in 30 patients (Group A), of whom 20, or 67%, had meningeal contrast enhancement on their initial MRI. Of the 80 patients who presented initially with other than headache (Group B), 60(75%), did not have meningeal enhancement on their initial MRI (p-value <0.001).
Patients with neurosarcoidosis who present with headache as an initial symptom are more likely to have meningeal contrast enhancement as compared to those who present with other symptomatology. This suggests a clinicoradiologic link between headache and meningeal disruption in patients with neurosarcoidosis.
Authors/Disclosures
Yamin Sallowm, MD (Yamin Sallowm)
PRESENTER
Dr. Sallowm has nothing to disclose.
Muhammad Affan, MD (University of Minnesota) Dr. Affan has nothing to disclose.
Mirela Cerghet, MD, PhD, FAAN (Henry Ford Hospital) Dr. Cerghet has nothing to disclose.
Ashhar Ali, DO, FAAN (Henry Ford) Dr. Ali has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Pfizer. Dr. Ali has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Ebsco.